Trial Profile
A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) [gefitinib] In Patients With Malignant Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Therapeutic Use
- 16 Jan 2013 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 16 Jan 2013 Actual initiation date (Sep 2001) added as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.